Status: Recruiting
Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer.
Participants needed: 16
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Coordination Pharmaceuticals, Inc.Updated: Sep 17, 2025Locations: 1
Eligibility criteria
Diagnosis of head-neck cancer that requires palliative radiotherapy [+11]
Have signs or symptoms of end organ failure, major chronic illnesses other than... [+6]